Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01155583 · ClinicalTrials.gov registry record · Phase 1
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT01155583 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 45 participants.
The verdict
NCT01155583, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as azacitidine and dexamethasone, work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving azacitidine together with lenalidomide and dexamethasone may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of azacitidine when given together with lenalidomide and low-dose dexamethasone in treating patients with relapsed or refractory multiple myeloma.
Interventions
- DRUG azacitidine
- DRUG dexamethasone
- DRUG lenalidomide
- OTHER gene expression analysis
- OTHER DNA methylation analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2010-06 |
| Est. Completion | 2018-11-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01155583
The ClinicalTrials.gov registry entry for NCT01155583 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which azacitidine is the first listed.
NCT01155583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01155583 about?
NCT01155583 is a clinical study titled "Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma". RATIONALE: Drugs used in chemotherapy, such as azacitidine and dexamethasone, work in different ways to stop the growth of cancer cells either by killing the cells or by stopping them from dividing. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and sto...
What is the current status of trial NCT01155583?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2010-06. Estimated completion is 2018-11-06.
What interventions are being tested in trial NCT01155583?
The interventions under investigation include: azacitidine (DRUG), dexamethasone (DRUG), lenalidomide (DRUG), gene expression analysis (OTHER), DNA methylation analysis (OTHER).
Who is sponsoring clinical trial NCT01155583?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.